Top Industry Leaders in the Anaplasmosis Treatment Market
Latest Anaplasmosis Treatment Companies Updates:
Pfizer announces Phase 3 trial results for Xywav (dapoxetine) for the treatment of anaplasmosis: These promising results indicate Xywav's potential effectiveness in controlling anaplasma infections, offering a new treatment option in the future.
Emergent Biosolutions completes a successful Phase 2a clinical trial for its investigational vaccine candidate for anaplasmosis: This development marks a significant step forward in preventative measures against the disease
Abbott Laboratories receives FDA approval for its Afinitor® (everolimus) for the treatment of certain cancers, including anaplasmosis-associated malignant hemangiomas: This expands the potential applications of Afinitor, offering a targeted therapy for certain rare complications of anaplasmosis.
List of Anaplasmosis Treatment Key companies in the market:
- Wyeth Pharmaceuticals (U.S.)
- Merck Sharp & Dohme (France)
- Boehringer Ingelheim (France)
- Bristol-Myers Squibb and Company (U.S.)
- Glaxosmithkline Inc. (U.S.)
- Aventis Pharma (Canada)
- Mylan Pharmaceuticals (U.S.)
- Pfizer Inc. (U.S.)
- Teva Pharmaceuticals (Israel)
- Shire (U.S.)
- Procter & Gamble, (U.S.)
- Duramed Pharmaceuticals (U.S.)